SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending due to community buzz surrounding a rumored COEP merger and ongoing speculation about Elon Musk's X platform integrating cryptocurrency payments, potentially leveraging DOGE. The community is actively debating whether this signals a broader return of meme coin season.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu Crypto is trending with strong community conviction, driven by its consistent building of a permissionless brand that features real-world products and widespread IRL initiatives. Supporters are actively discussing its impressive resilience and upward price movement, making it a standout "conviction play" amid broader market turbulence.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as the crypto community actively debates a potential 'meme season,' driving notable price action and creating sharply divided discussions around its future trajectory. While many anticipate significant upward movement, others caution of imminent declines, with its performance closely watched alongside broader crypto market trends.

Moo Deng

MOODENG CRYPTO is attracting significant speculative interest and high trading volume, as the community rallies for another explosive pump, drawing comparisons to other top meme coins amid broader market anticipation for altcoin rallies.

PENN Entertainment, Inc. engages in the provision of integrated entertainment, sports content, and casino gaming services. It operates through the following business segments: Northeast, South, West, Midwest, Interactive, and Other. The Northeast segment includes Ameristar East Chicago, Hollywood Casino, Hollywood Gaming, Marquee, and Plainridge Park Casino operations. The South segment manages 1st Jackpot Casino, Ameristar Vicksburg, Boomtown, Hollywood Casino Gulf Coast, Hollywood Casino Tunica, L’Auberge, and Margaritaville Resort Casino. The West segment is involved in Ameristar Black Hawk, Cactus Petes and Horseshu, M Resort Spa Casino, and Zia Park Casino operations. The Midwest segment focuses on Ameristar Council Bluffs, Argosy Casino, Hollywood Casino, Prairie State Gaming, and River City Casino operations. The Interactive segment refers to an online gaming portfolio which includes ESPN BET, Hollywood Casino, theScore Bet, and PENN Game Studios. The Other segment consists of stand-alone racing operations, namely Sanford-Orlando Kennel Club, Sam Houston, and Valley Race Park. The company was founded by Peter M. Carlino in 1982 and is headquartered in Wyomissing, PA.

PENN Entertainment Inc

PENN Entertainment Inc.

PENN Entertainment is trending as its high-profile ESPN Bet partnership concludes and is replaced by DraftKings, intensifying community frustration with CEO Jay Snowden's perceived missteps in digital strategy and a "disconnected from reality" stock valuation. Shareholder discussions focus on the underlying value of regional casino assets and hopes for activist intervention to spin off the online segment.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian (TEAM) is trending due to a significant stock price decline, currently down notably this year, despite reporting solid earnings amidst broader software sector fears about AI disruption. The community is sharply divided, with some viewing the stock as an undervalued opportunity at current levels, while others fear continued downside given persistent AI threats and concerns over insider selling.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

The AMP community is actively discussing the imminent passage of the "Clarity Act," anticipating it will solidify AMP's classification as a pivotal digital commodity for collateralized payments, a development many believe will unlock significant utility and drive a major market re-evaluation despite years of price stagnation.

Yearn Finance is a suite of products in Decentralized Finance (DeFi) that provides lending aggregation, yield generation, and insurance on the Ethereum blockchain. The protocol is maintained by various independent developers and is governed by YFI holders.  It started out as a passion project by Andre Cronje to automate the process of switching capital between lending platforms in search of the best yield offered, as the lending yield is a floating rate rather than fixed rate. Funds are shifted between dYdX, AAVE, and Compound automatically as interest rates change between these protocols.   The service offered includes major USD tokens such as DAI, USDT, USDC, and TUSD. For example, if a user deposits DAI into yearn.finance, the user will receive yDAI token in return, which is a yield-bearing DAI token.   Later on, it collaborated with Curve Finance to release a yield-bearing USD tokens pool that includes four y-tokens: yDAI, yUSDT, yUSDC and yTUSD, it is named as yUSD.   Yearn Finance debuted the vault feature after its token launch, igniting a frenzy on automated yield farming and is considered the initiator of the category of yield farming aggregator. Basically, the vault will help users to claim yield farming rewards and sell it for the underlying assets.   Vaults benefit users by socializing gas costs, automating the yield generation and rebalancing process, and automatically shifting capital as opportunities arise. End users also do not need to have proficient knowledge of the underlying protocols involved or DeFi, thus the Vaults represent a passive-investing strategy. It is akin to a crypto hedge fund where the aim is to increase the amount of assets that users deposited.

yearn.finance

Yearn.finance ($YFI) is actively discussed as a sleeping giant poised for an explosive 'DeFi season,' with many in the community anticipating significant gains due to its extremely limited token supply. Enthusiasts are accumulating, believing YFI is severely undervalued and will benefit greatly from a rotation of capital into decentralized finance.

SSR Mining, Inc. is a gold company with assets located in four jurisdictions: the USA, Turkiye, Canada, and Argentina, which engages in the operation, acquisition, exploration and development of precious metal resource properties. The firm produces gold ore as well as copper, silver, lead and zinc concentrates. It operates through the following business segments: Copler, Marigold, Seabee and Puna. The Copler, Marigold, Seabee, and Puna segments represent its four operating mine sites. The company was founded on December 11, 1946 and is headquartered in Denver, CO.

SSR Mining Inc

SSRM is a key talking point as investors anticipate strong upcoming earnings, driven by robust precious metal prices and its CC&V mine's performance, though ongoing discussions also center on its valuation, operational risks, and the uncertain status of its Copler mine.

EOG Resources, Inc. engages in the exploration, development, production and marketing of crude oil and natural gas. It operates through the United States, Trinidad, and Other International geographical segments. The Other International segment includes China and Canada operations. The company was founded in 1985 and is headquartered in Houston, TX.

EOG Resources, Inc.

EOG Resources is trending after announcing a $5.6 billion acquisition of Encino Acquisition Partners, significantly expanding its Utica shale position, alongside a 5% dividend increase and a $5 billion share repurchase authorization. These strategic moves are fueling bullish sentiment among investors who highlight the company's strong operational efficiency, robust cash flow, and commitment to shareholder returns amidst mixed analyst views on the broader energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Klotho Neurosciences to Present at the Biotech Showcase 2026

Klotho Neurosciences to Present at the Biotech Showcase 2026 Klotho Neurosciences to Present at the Biotech Showcase 2026 PR Newswire NEW YORK, Jan. 8, 2026 NEW YORK, Jan. 8, 2026 /PRNewswire...

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award...

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston PR Newswire NEW YORK, Oct. 16, 2025 NEW YORK, Oct. 16, 2025...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202.The designation is reserved for treatments targeting rare diseases and comes with several incentives to support development.&nbsp;These include seven years of market exclusivity, tax credits for clinical trials, and a waiver of the generic drug user fee amendments (GDUFA) user fee, independent of existing intellectual property rights.At the close on Thursday, shares of&nbsp;<a href="https://stocktwits.com/symbol/KLTO">Klotho Neurosciences</a> rose 6.6% to $1.46, before slipping 6.9% to $1.36 in after-hours trading.Last month, the company reported efforts to move forward with manufacturing and process development in preparation for clinical trials of KLTO-202.&nbsp;Klotho holds rights to a unique RNA splice variant of the human alpha‑Klotho gene, licensed from the Autonomous University of Barcelona.&nbsp;This variant produces the secreted form of Klotho protein (s‑KL), known for its neuroprotective properties in the brain and spinal cord.Animal studies conducted in mouse and non-human primate models of accelerated aging, Alzheimer's disease, and ALS have demonstrated that boosting s‑KL through gene therapy yields therapeutic benefits across all tested models, according to peer-reviewed journals.&nbsp;These findings support KLTO-202’s progression into clinical development.The company expects that process development and manufacturing will take about eight months, followed by four to six months of FDA meetings, mandated animal safety studies, an investigational new drug (IND) filing, and site preparations.&nbsp;A single-dose Phase I/II trial in ALS patients is planned for the third quarter of next year.&nbsp;In a statement, CEO Joseph Sinkule said that the therapy’s goal is to deliver therapeutic s‑KL concentrations to blood, brain, and muscle tissue.KLTO-202, which uses a muscle-specific desmin promoter to drive s‑KL expression at the neuromuscular junction, remains unapproved for human use.On Stocktwits, retail sentiment for Kloto was ‘bullish’ amid ‘high’ message volume.Kloto’s stock has more than doubled in value so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/china-s-byd-chery-accused-of-subsidy-misuse-as-ev-audit-flags-121-m-in-claims/ch8c5XCR5mQ">China’s BYD, Chery Accused Of Subsidy Misuse As EV Audit Flags $121M In Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kloto Neurosciences (KLTO) said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. (Photo credit: Getty Images)

Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical trials, and a waiver of the user fee for its ALS gene therapy.

Equity

Klotho Neurosciences (KLTO) shares exploded over 780% on Monday, their biggest single-day gain on record, after the company announced breakthrough preclinical results tied to its anti-aging gene therapy.The Omaha, Nebraska-based biotech said boosting levels of a naturally occurring protein called s-KL (secreted Klotho) extended lifespan in mice by 20% and reduced signs of aging across multiple organ systems.&nbsp;The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models."The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span," said CEO Joseph Sinkule.&nbsp;Klotho owns exclusive global rights to the patented therapy, based on pioneering work from researchers at Universitat Autònoma de Barcelona. The company said its patent coverage spans the U.S., Europe, and China.Earlier studies had shown that mice with increased Klotho expression could live up to 40% longer.Retail Traders Go WildThe update triggered a retail frenzy on Stocktwits as 24-hour message volume about KLTO jumped by 250,400% — the biggest surge in the healthcare sector — while the follower count spiked by over 134%.Sentiment score peaked at ‘extremely bullish’ levels (100/100) by the end of Monday.<figure class="image"><img style="aspect-ratio:1318/914;" src="https://news.stocktwits-cdn.com/KLTO_sentiment_and_message_volume_as_of_Jun_9_png_d3adf0d02d.webp" alt="KLTO sentiment and message volume as of Jun 9.png" width="1318" height="914"><figcaption>KLTO sentiment and message volume as of Jun 9. | source: Stocktwits</figcaption></figure>One user predicted the stock would surge nearly fivefold to $5.<stembedurl>https://stocktwits.com/Kcricket33/message/617354438</stembedurl>"Pretty wild news, obviously digested well today… will watch for continuation tomorrow using the pivot of today's highs in confluence with trend support as entry criteria. Range to $2.8, $3+," said another.<stembedurl>https://stocktwits.com/KevMomentum/message/617353716</stembedurl>Klotho is targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, leveraging s-KL in both DNA/RNA therapies and genomics-based diagnostics.<a href="https://stocktwits.com/symbol/KLTO">KLTO stock</a> is now up over 271% YTD, returning to levels last seen in July 2024.&nbsp;However, short interest has also climbed, rising from 1.1% in January to 7.1% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models.

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

Klotho Neurosciences Inc.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

KLTO
Klotho Neurosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest KLTO News

KLTOKlotho Neurosciences Inc.